Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

Merlintrader’s Daily Briefing

Friday, August 7, 2026, morning edition. Wall Street closed lower on Thursday and the Dow’s record-setting run ended: the blue-chip index fell 464.02 points, or 0.85%, to 53,885.10, while the S&P 500 slipped 0.18% to 7,709.96 and the Nasdaq Composite eased 0.06% to 26,348.35. Memory names led the drag, Symbotic sold off on a beat and SoundHound rallied on record revenue. The Food and Drug Administration granted accelerated approval to Replimune’s melanoma therapy after two prior rejections, and Iovance posted its largest quarter yet. Overnight, Middle East risk pushed Brent back above $83 after Yemen’s Houthis struck Saudi Arabia, and Treasury yields rose with it. Everything now waits on the July employment report at 8:30 a.m. Eastern, a print that markets are treating as a live input into whether the Federal Reserve moves next month.

Thursday’s close
  • Indexes — The Dow Jones Industrial Average lost 464.02 points, or 0.85%, to 53,885.10, ending its winning streak after a run of record closes. The S&P 500 fell 0.18% to 7,709.96 and the Nasdaq Composite eased 0.06% to 26,348.35, a narrow decline that masked a wide spread between the day’s leaders and its losers.Tape
  • Memory — The memory complex was the clearest drag. Sandisk fell 5.40% to $1,350.50 and Western Digital 5.36% to $519.17 after guidance that came in below the level the market had been discounting, extending the pattern of punishing reactions to anything that reads as a slower revenue path for AI-linked hardware.Semis
  • $SYM — Symbotic dropped 14.88% to $39.60 despite beating on the top line. Fiscal third-quarter revenue was $720.8 million, up 22% year on year and ahead of the roughly $715 million consensus, and the company swung to a $55 million profit from a $21 million loss a year earlier. Fourth-quarter guidance of $700-720 million in revenue and $80-85 million of adjusted EBITDA framed the debate as one about the pace of margin expansion rather than demand.Earnings
  • $SOUN — SoundHound AI rose 10.11% to $7.08 on record second-quarter revenue of $61.9 million, up 45% year on year, with adjusted loss per share of $0.02 and $203 million of cash and no debt. Full-year guidance was raised to a midpoint near $245 million, a figure that excludes the pending LivePerson acquisition.Earnings
  • $PLTR — Palantir slipped 1.58% to $155.92, giving back part of the move that followed Monday’s report, while the wider software tape stayed sensitive to any guidance that implies heavier spending to hold the same growth rate.Software
After the bell
  • $ABNB — Airbnb reported adjusted earnings of $1.37 a share against roughly $1.26 expected, on revenue of $3.61 billion, up 17% year on year and above the $3.58 billion consensus. Gross booking value was $27.2 billion, up 16%, and free cash flow reached $1.253 billion, up close to 32%. The company lifted its full-year outlook and the shares rose about 11% in extended trading from a $151.64 close.Earnings
  • $NET — Cloudflare reported revenue of $696.1 million, up 36% year on year, and 4,698 customers spending more than $100,000 a year, up 27% with a record 986 net additions in the quarter. Full-year guidance was raised to $2.864-2.870 billion. The stock closed the regular session down 2.91% at $284.43 and then jumped roughly 17% after hours.Earnings
  • $LYFT — Lyft earned $0.13 a share against about $0.15 expected, on revenue of $1.84 billion that beat the $1.81 billion consensus. Gross bookings rose 23% to $5.5 billion, active riders 17% to 30.5 million and rides 12% to 262 million. The shares added roughly 1% after hours.Earnings
Today: the July employment report
  • Consensus — The Bureau of Labor Statistics releases the July employment situation at 8:30 a.m. Eastern. Forecasts centre on a gain of 80,000 jobs after 57,000 in June, with the unemployment rate expected to hold at 4.2%. The distance between a 57,000 print and an 80,000 print is small in absolute terms and large in what it implies about the trend.Macro
  • Private payrolls — The setup is a soft one. ADP Research counted 44,000 private-sector jobs added in July, the smallest monthly gain since January, which is the main reason the consensus for the official figure sits below six figures.Macro
  • Fed pricing — Rate expectations are unusually unsettled. Markets have not converged on what the Federal Reserve does next month, with a rate increase currently priced closer to a coin toss than to a tail risk, an outcome that puts unusual weight on a single labour reading.Policy
  • The mechanics — Michael Feroli, chief US economist at JPMorgan, framed Friday’s release as a print likely to trade as good news being bad news: a strong number reinforces higher-for-longer pricing and pushes yields up, while a soft number lets yields ease and shifts policy expectations toward a more dovish path.Policy
Rates, dollar and metals
  • Treasuries — Higher oil lifted yields. The two-year note yield held at 4.2496% in Asian hours after rising seven basis points overnight, while the ten-year steadied at 4.6821% having added five basis points. The move came from the inflation side of the curve rather than from growth expectations.Rates
  • Dollar — The dollar was steady in Asia after bouncing overnight. Against the yen it traded at 158.38, having risen 0.4% overnight to break back above its 200-day average near 158, a level that matters after last week’s joint intervention by Japan and the United States.FX
  • Gold — Spot gold rose 0.7% to $4,268 an ounce and was heading for its strongest week since January, with silver up 1.3% to $62.29. Precious metals have been reacting to the same shift in rate expectations that has kept equity leadership narrow.Metals
Oil and the Strait of Hormuz
  • Brent — Brent crude futures gained 1.5% to $83.78 a barrel after jumping 3.8% in the previous session. Even after two days of gains the contract was still set for a weekly loss of about 7%, and it remains well below the $102 peak reached two weeks ago.Energy
  • Saudi Arabia — The escalation came from Yemen. Houthi forces attacked Saudi Arabia, a major crude supplier, and Riyadh warned that coordinated attacks by the Houthis and Iran-backed Iraqi militias were imminent. That reintroduced a supply risk that the market had spent the previous three sessions discounting.Geopolitics
  • Iran — Iran is reviewing a preliminary bill that would bar United States, Israeli and other vessels it designates as hostile from transiting the Strait of Hormuz, with fines of up to 20% of a ship’s cargo value for violations. The draft moves in the opposite direction from the temporary shipping-route arrangement with Oman that had been described this week as close to completion.Geopolitics
  • Flows — Saudi crude shipments to the United States have fallen to zero as American refiners pivot to other barrels, a reallocation that changes who is exposed to a Hormuz disruption without changing the size of the disruption itself.Energy
Biotech: an approval that had been refused twice
  • $REPL — The Food and Drug Administration granted accelerated approval on Thursday to Replimune’s TUDRIQEV, vusolimogene oderparepvec-wtpg and previously known as RP1, in combination with nivolumab, for adults with unresectable advanced cutaneous melanoma whose disease progressed on an anti-PD-1 based regimen. The shares rose 8.71% to $12.86.FDA
  • The path — The approval rests on objective response rate and duration of response, with continued approval contingent on confirmatory evidence of clinical benefit. It follows a complete response letter in which the agency had judged the phase 2 IGNYTE trial insufficient, and an advisory committee that voted 10-3 the previous week that the efficacy data were evaluable and clinically meaningful.FDA
  • $IOVA — Iovance Biotherapeutics reported record second-quarter revenue of about $99.3 million, up 66% year on year and 39% from the first quarter, with Amtagvi contributing roughly $91 million and beating the company’s own guidance range by $10-12 million. Gross margin improved to 56%. The stock closed up 43.09% at $6.21, its largest single-day gain in more than six years.Earnings
  • The follow-through — Iovance said it is reviewing its 2026 revenue guidance of $350-370 million in light of demand, with an update expected in the third quarter. The commercial footprint stands at more than 95 authorised treatment centres with at least 110 targeted by year-end, and lifileucel received fast track designation in soft tissue sarcomas.Pipeline
Biotech movers
  • $AKBA — Akebia Therapeutics fell 26.02% to $0.95 after second-quarter revenue of $49.13 million missed consensus. Vafseo contributed $21.3 million and continued to grow, but Auryxia sales roughly halved, leaving the transition between the two products as the whole of the story.Earnings
  • $DCTH — Delcath Systems rose 22.49% to $15.47 after reporting second-quarter results showing HEPZATO treatment volumes up about 30% year on year and $95.9 million of cash and investments at June 30.Earnings
  • Gainers — The broader biotech tape was firm. AbCellera added 10.30% to $6.53, Adma Biologics 8.64% to $10.06, Regenxbio 7.43% to $11.28 and Viridian Therapeutics 6.83% to $22.51.Sector
Space and defense: three reports, three different problems
  • $RDW — Redwire posted record second-quarter revenue of $117.1 million against roughly $107.9 million expected, with a loss of $0.09 a share versus $0.16 expected, a record 27.8% gross margin and a record $542.1 million backlog. Stalker uncrewed aircraft orders added $21.5 million in the quarter after $20 million in the first. The stock rose 10.35% to $11.83.Earnings
  • $BKSY — BlackSky reported second-quarter revenue of $33.32 million, up 50.1% year on year and above the $29.76 million consensus, with a loss of $0.32 a share against $0.38 expected and positive adjusted EBITDA of $4.7 million on a $20.8 million net loss. Full-year guidance of $130-150 million in revenue was reaffirmed. The shares gained 10.37% to $27.79.Earnings
  • $RCAT — Red Cat Holdings reported second-quarter revenue of $20.2 million, up 527% year on year, with gross profit of $3.3 million at a 16.1% margin and a loss of $0.26 a share against about $0.18 expected. The stock finished essentially flat at $8.67, a reaction that reads as the market accepting the revenue ramp while waiting on the margin.Earnings
  • The group — Intuitive Machines rose 6.72% to $14.93 ahead of its own report, AeroVironment added 1.82% to $171.12 and Rocket Lab 1.14% to $75.67. AST SpaceMobile eased 1.49% to $67.36 and Unusual Machines fell 5.83% to $24.23.Sector
Asia, Europe and China
  • Japan — The Nikkei fell 0.5% on Friday but was on track for a weekly gain of 1.7%. Japan confirmed it intervened in the currency market on three days in the spring, and the yen has since surrendered close to half the gains it made after last week’s coordinated action.Asia
  • Korea — The Kospi also fell 0.5% and was down 5.1% on the week, a seventh consecutive weekly decline for an index that had doubled in the first half of the year on demand for AI-linked chip stocks. The unwind there has been the cleanest expression of the AI-cost debate anywhere in global equities.Asia
  • China — The CSI 300 rose 0.8% after export data showed shipments still running strongly enough to carry the economy. MSCI’s broadest index of Asia-Pacific shares outside Japan slipped 0.1% and was down 0.5% for the week.Asia
  • Europe — Pan-European stock futures pointed 0.2% lower ahead of the open, with the region taking its direction from the same payrolls print rather than from anything domestic.Europe
Policy and corporate
  • Tariffs — A 15% tariff was imposed on a key material used in semiconductor and solar panel manufacturing, a measure that lands on the input side of two supply chains already carrying elevated cost expectations.Policy
  • $META — Meta Platforms was found to be a public nuisance in a ruling carrying $567 million in damages, one of the larger single figures yet attached to the litigation running against the large platforms.Legal
What Friday sets up
  • The print — Everything in the session ahead routes through 8:30 a.m. Eastern. A payrolls figure near or above consensus keeps the higher-for-longer framing intact and leaves the equity market working against rising yields; a soft figure eases yields and takes some pressure off the long-duration part of the tape.Setup
  • The week — The S&P 500 and the Dow enter the session having spent most of the week making and then giving back records, while the semiconductor and memory complex has done the opposite. Which of those two tapes the payrolls number validates is the question the close will answer.Setup
Transparency
  • Sourcing — Index levels and single-stock closes are Thursday, August 6 prints. Overnight quotes for oil, yields, currencies and metals are as of the Asian session on Friday, August 7 and will have moved by the US open. Consensus figures for the employment report are market forecasts, not official data.Method
  • Not confirmed — Merlintrader could not identify a confirmed company-specific catalyst behind the Thursday moves in Intuitive Machines, Zevra Therapeutics, which rose 12.82% to $11.88, or POET Technologies, which rose 5.44% to $8.53, and is not attributing a cause to them.Method
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 31 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory outcome has not yet been publicly disclosed. October and later events are excluded from this widget.

35Active
17FDA / Reg
18Data / Filing
Jul 31Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXPKETAFREEJul 29*PendingGDUFA goal passed; public FDA outcome pending

NRx Pharmaceuticals. The FDA-assigned July 29 GDUFA goal date for the KETAFREE preservative-free IV ketamine ANDA has passed. As of the July 31 update, no approval, tentative approval or complete response had been publicly disclosed by the company, so the item remains active as an unresolved regulatory watch. This is an ANDA event, not a PDUFA for NRX-100 or NRX-101.

$REPLRP1Aug 2PDUFAMelanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFAmRNA seasonal flu

Moderna. Following the FDA advisory committee’s unanimous June endorsement, the BLA PDUFA for the mRNA seasonal flu vaccine candidate in adults 50+ is due August 5. Approval remains pending; the event is more of a platform and lifecycle read-through than a pure small-cap binary.

$REGNgaretosmabAugFDAFOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDATau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22Extreme riskPDUFA after 9–3 negative efficacy vote

Capricor. The BLA remains under FDA review for the treatment of DMD cardiomyopathy, but the July 29 advisory committee voted 9–3 that the available evidence did not provide substantial evidence of effectiveness. FDA is not legally bound by the vote, yet the combination of the negative panel recommendation, disputed endpoint analyses and prior CRL history makes the August 22 decision an extreme-risk regulatory event.

$RAREDTX401Aug 23BLAGSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLASC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDAOnce-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFAPolycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$GSKzidesamtinibSep 18NDAROS1+ NSCLC · acquired Nuvalent asset

GSK / former Nuvalent. GSK completed its acquisition of Nuvalent on July 15 and $NUVL ceased trading. The September 18 FDA PDUFA for zidesamtinib in TKI-pretreated ROS1-positive non-small-cell lung cancer remains active, but it is now a large-cap $GSK regulatory catalyst rather than an $NUVL trading event.

$RAREUX111Sep 19RiskSanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDAAlexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDASuperficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLASpinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDADermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLAHuntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugDataSANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3DataAL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearDataEndometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3DataWet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3DataSLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3DataDECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugDataZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3DataIBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFRORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3DataStargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDAFocal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDAAchondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDAALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLARolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLAHS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$NRXP$REPL$CAPR$RARE$GSK$IONS$SRRK$AMLX$PHVS$QURE

Board rule

Only unresolved catalysts through September are shown. Past events are removed once an outcome is publicly confirmed; a passed target date may remain visible when the FDA action has not yet been disclosed. $NRXP therefore remains marked Pending after its July 29 KETAFREE GDUFA goal date. October and later events are intentionally excluded. $NUVL was acquired by GSK and ceased trading, so the September zidesamtinib catalyst is shown under $GSK. Events carrying only Q3 guidance must be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events.Full catalyst calendarFDASEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.